This phase II trial is testing a new biological therapy (tisagenlecleucel) that is made using a patient's T-Cells, to treat people who have been diagnosed with Follicular Lymphoma but have gotten worse or not responded to other therapies.
This trial is treating patients with follicular lymphoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma
This trial is treating patients with refractory or relapsed Follicular Lymphoma (Grade 1, 2, 3A). Tisagenlecleucel(CTL019) will be administered as a single infusion.
Recruiting Hospitals Read More